NIH Conflict Of Interest Reg Aims To Bolster Public Trust As Links To Industry Flourish
This article was originally published in The Pink Sheet Daily
Upgrade of the 1995 regs is "an insurance plan" against potential trouble downstream, NIH Director Collins says, but some advocacy groups wanted broader disclosure.
You may also be interested in...
A government watchdog group is worried that the White House Office of Management and Budget is about to take the teeth out of the National Institute of Health's proposed new conflict of interest rule.
Toxicity testing is one area in which NIH Director Francis Collins expects the proposed National Center for Advancing Translational Science to help industry speed up drug development.
At Bio-Windhover's Pharmaceutical Strategic Outlook conference, Susan Desmond-Hellmann discussed UCSF's evolving relationships with big pharma.